Vision loss after anti-VEGF likely to be endophthalmitis

A review of the published case series of endophthalmitis following intravitreal injection indicates that those presenting with visual acuity 20/200 or less more than 24 hours after the injection were very likely to have endophthalmitis, while those presenting with a similar loss of vision during the first 24 hours were more likely to be due to different causes. The study's investigators used a Pubmed search of the literature and retrieved 12 case series, which together with their own case series included a total of 133 patients. The researchers found that the records showed that among those cases where antibiotics were deemed unnecessary the mean time to presentation was one day, but in those who received antibiotics the mean time to presentation was three days, whether or not their biopsy was positive for bacterial pathogens.
• (Hoevenaars et al, Ophthalmologica 2012, DOI: 10.1159/000339584.)Â
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.